NTIDC research is proud to be the only site in Dallas that has been dosing with long-acting, injectable HIV-treatment since 2014.

Gilead’s new capsid inhibitor GS-6207 has started its phase 1b trial with the potential for 3 month dosing. The capsid inhibitor is currently being dosed by a subcutaneous injection but Gilead is attempting to develop a oral formulation of the antiretroviral.

At the 2019 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle, a second case of an HIV positive adult cleared of the HIV virus after he received a bone marrow transplant from an HIV resistant donor was presented.